


LIST OF TABLES

	Page
Table I	11
Table 1.1	21
Table 1.2	21
Table 1.3	22
Table 1.4	22
Table 1.5	23
Table 1.6	23
Table 1.7	24
Table 1.8	24
Table 1.9	25
Table 1.10	26
Table 1.11	27
Table 1.12	28
Table 1.13	29
Table 1.14	30
Table 1.15	31
Table 2.1	36
Table 2.2	37
Table 2.3	37
Table 2.4	37
Table 2.5	39
Table 2.6	39
Table 2.7	40
Table 2.8	41
Table 2.9	41
Table 2.10	42
Table 2.11	42



	Page
Table 2.12	Method of cancer staging among invasive breast cancer patients (N=10,787)
Table 2.13	Histological type of invasive breast cancer (N=21,616)
Table 2.14	Grading, multifocality and multicentricity of invasive breast cancer (N=21,616)
Table 2.15	Biological characteristics of invasive breast cancer (N=21,616)
Table 2.16	Biological subtypes of invasive tumours by cancer stage (N=20,194)
Table 2.17	Histological type, grading, multifocality and multicentricity of in situ breast cancer (N=3,450)
Table 2.18	Biological characteristics of in situ breast cancer (N=3,450)
Table 2.19	Number of treatment modalities by cancer stage (N=24,480)
Table 2.20	Use of surgery for patients with invasive or in situ cancer
Table 2.21	Coverage of regional lymph nodes by adjuvant locoregional radiotherapy (N=9,017)
Table 2.22	Use of chemotherapy by age group and cancer stage at diagnosis (N=20,368)
Table 2.23	Use of chemotherapy by cancer stage across diagnosis year groups (N=20,960)
Table 2.24	Use of chemotherapy by biological subtype across diagnosis year groups (N=20,194)
Table 2.25	Follow-up of patients (N=22,768)
Table 2.26	Recurrence pattern of patients (N=21,995)
Table 2.27	Locoregional and distant recurrence among invasive breast cancer patients by cancer stage (N=18,413)
Table 2.28	Locoregional recurrence by type of surgery received and cancer stage at diagnosis
Table 2.29	Sites involved in locoregional recurrence (N=935)
Table 2.30	Sites involved in distant recurrence (N=1,073)
Table 2.31	Time for organ-specific metastasis and distribution of the biological subtypes of patients
Table 2.32	Characteristics of breast cancer-specific deaths (N=1,780)
Table 3.1	Psychosocial impact of breast cancer
Table 3.2	Psychosocial adjustments and coping strategies for survivorship

LIST OF FIGURES

		Page
Figure I	Distribution of year of diagnosis of HKBCR participants in the past 15 years	7
Figure II	Side-by-side comparisons on age and stage distributions in the 2018-2023 cohort	11
Figure 1.1	Distribution of age at diagnosis (N=28,806)	17
Figure 1.2	Occupation of patient cohort (N=28,806)	17
Figure 1.3	Education level of patient cohort (N=28,806)	18
Figure 1.4	Monthly household income (HK\$) of patient cohort (N=16,629)	18
Figure 1.5	District of residence of patient cohort (N=28,806)	18
Figure 1.6	Bra band size of patient cohort (N=23,020)	19
Figure 1.7	Bra cup size of patient cohort (N=20,064)	19
Figure 1.8	Dietary habits at diagnosis (N=28,806)	20
Figure 1.9	Exercise habits at diagnosis (N=28,806)	20
Figure 1.10	Stress level at diagnosis (N=28,806)	20
Figure 1.11	Body mass index at diagnosis (N=28,806)	21
Figure 1.12	Distribution of risk factors among patients at diagnosis (N=28,357)	25
Figure 1.13	Distribution of risk factors by diagnosis year group (N=28,357)	25
Figure 2.1	Methods of first breast cancer detection in the patient cohort (N=24,430)	36
Figure 2.2	Major presenting symptoms of self-detected breast cancer in the patient cohort (N=19,210)	38
Figure 2.3	Time interval between symptom onset and first medical consultation for patients who self-detected their cancer (N=6,884)	38
Figure 2.4	Locations of malignant tumour on breasts within the patient cohort (N=25,618)	40
Figure 2.5	Mammographic density of breasts of patients diagnosed through mammography (N=13,134)	41
Figure 2.6	Use of PET scan among patients who had cancer staging by cancer stage (N=10,787)	44
Figure 2.7	Cancer stage at diagnosis (N=25,618)	44
Figure 2.8	Distribution of cancer stage by diagnosis year group (N=25,618)	45
Figure 2.9	Distribution of tumour size (cm) of invasive breast cancer (N=21,616)	45
Figure 2.10	Number of positive axillary lymph nodes among patients with invasive breast cancer (N=18,733)	46
Figure 2.11	Distribution of tumour size (cm) in invasive cancer with negative or positive nodal status (N=17,816)	46
Figure 2.12	Distribution of tumour size (cm) of in situ breast cancer (N=2,822)	46
Figure 2.13	Type of breast surgery by age group (N=23,507)	54
Figure 2.14	Type of breast surgery by invasive tumour size (cm) (N=19,033)	54
Figure 2.15	Type of breast surgery by cancer stage (N=24,167)	54



	Page
Figure 2.16 Type of breast surgery by type of medical service (N=23,368)	54
Figure 2.17 Type of breast surgery by diagnosis year group (N=24,167)	55
Figure 2.18 Type of nodal surgery by clinical nodal status (N=22,689)	55
Figure 2.19 Type of nodal surgery for invasive cancer by cancer stage (N=20,474)	55
Figure 2.20 Type of nodal surgery for invasive cancer by diagnosis year group (N=20,474)	56
Figure 2.21 Number of positive nodes by type of nodal surgery (N=20,366)	56
Figure 2.22 Use of radiotherapy among patients who underwent breast-conserving surgery by cancer stage (N=9,340)	57
Figure 2.23 Use of radiotherapy among patients who underwent mastectomy by cancer stage (N=14,384)	57
Figure 2.24 Use of radiotherapy among patients with breast-conserving surgery by diagnosis year group (N=9,340)	57
Figure 2.25 Use of radiotherapy among patients with mastectomy by diagnosis year group (N=14,384)	58
Figure 2.26 Use of chemotherapy by cancer stage (N=20,960)	59
Figure 2.27 Use of chemotherapy by biological subtype (N=20,194)	59
Figure 2.28 Use of chemotherapy by diagnosis year group (N=20,960)	59
Figure 2.29 Use of neoadjuvant chemotherapy by cancer stage across diagnosis year groups (N=13,469)	61
Figure 2.30 Use of neoadjuvant chemotherapy by biological subtype across diagnosis year groups (N=13,007)	61
Figure 2.31 Type of first generation chemotherapy regimens (non-HER2) used in neoadjuvant setting (N=143)	62
Figure 2.32 Type of second generation chemotherapy regimens (non-HER2) used in neoadjuvant setting (N=128)	62
Figure 2.33 Type of third generation chemotherapy regimens (non-HER2) used in neoadjuvant setting (N=698)	62
Figure 2.34 Type of HER2 regimens used in neoadjuvant setting (N=619)	62
Figure 2.35 Type of chemotherapy regimens used by biological subtype in neoadjuvant setting (N=1,545)	63
Figure 2.36 Type of first generation chemotherapy regimens (non-HER2) used in adjuvant setting (N=1,489)	64
Figure 2.37 Type of second generation chemotherapy regimens (non-HER2) used in adjuvant setting (N=2,683)	64
Figure 2.38 Type of third generation chemotherapy regimens (non-HER2) used in adjuvant setting (N=2,840)	64
Figure 2.39 Type of HER2 regimens used in adjuvant setting (N=2,371)	64
Figure 2.40 Type of chemotherapy regimens used by biological subtype in adjuvant setting (N=10,081)	65
Figure 2.41 Type of chemotherapy regimens used by cancer stage in adjuvant setting (N=10,250)	66
Figure 2.42 Type of chemotherapy regimens used by biological subtype in palliative setting (N=421)	67
Figure 2.43 Use of endocrine therapy by cancer stage (N=18,323)	68
Figure 2.44 Use of endocrine therapy by diagnosis year group (N=18,323)	68
Figure 2.45 Forms of endocrine therapy by age group (N=14,587)	69

	Page
Figure 2.46	Type of targeted therapy drugs used (N=3,569) 69
Figure 2.47	Use of anti-HER2 targeted therapy in HER2-positive patients by cancer stage (N=4,262) 70
Figure 2.48	Use of anti-HER2 targeted therapy in HER2-positive patients by diagnosis year group (N=4,262) 70
Figure 2.49	Type of complementary and alternative therapies used (N=7,700) 70
Figure 2.50	10-year overall survival of the patient cohort (N=22,768) 74
Figure 2.51	10-year overall survival by cancer stage (N=21,782) 74
Figure 3.1	Level of physical discomfort after surgery (N=21,307) 77
Figure 3.2	Level of physical discomfort by type of surgery (N=21,254) 77
Figure 3.3	Level of physical discomfort after radiotherapy (N=11,862) 78
Figure 3.4	Level of physical discomfort after radiotherapy by irradiated regions (N=7,793) 78
Figure 3.5	Level of physical discomfort after chemotherapy (N=11,835) 78
Figure 3.6	Level of physical discomfort after endocrine therapy (N=12,425) 78
Figure 3.7	Level of physical discomfort after targeted therapy (N=2,522) 79
Figure 3.8	Level of physical discomfort after complementary and alternative therapies (N=6,970) 79
Figure 3.9	Change in outlook on life by age group (N=20,981) 80
Figure 3.10	Change in self-image by age group (N=20,971) 81
Figure 3.11	Level of worry about recurrence by age group (N=21,003) 81